JBA
DNA icon

Johnson Bixby & Associates’s Ginkgo Bioworks DNA Stock Holding History

Johnson Bixby & Associates’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-250
Closed -$3.34K – 115
2024
Q2 		$3.34K Hold
250
– – ﹤0.01% 111
2024
Q1 		$11.6K Buy
+250
New +$12.9K ﹤0.01% 115

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Johnson Bixby & Associates's DNA Position: Q3 2024 in Review

Johnson Bixby & Associates sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 250 shares — an estimated $3.34K sold.

Johnson Bixby & Associates first reported a position in DNA in Q1 2024 and held it in 2 quarters. The position peaked at $11.6K in Q1 2024. 158 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Johnson Bixby & Associates reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Johnson Bixby & Associates sold 250 Ginkgo Bioworks shares in Q3 2024, an estimated $3.34K.
  • Johnson Bixby & Associates first reported a position in Ginkgo Bioworks in Q1 2024 and held it in 2 quarters.
  • Johnson Bixby & Associates's Ginkgo Bioworks position peaked at $11.6K in Q1 2024.
  • 158 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Johnson Bixby & Associates's 13F filing for Q3 2024, filed 10 Oct 2024.